Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: In vitro and in vivo studies

Cancer Immunology Immunotherapy

Volumn 48, Issue 4, 1999, Pages 179-188

  Leshem, Benny ^a   Dorfman, Yael ^a   Kedar, Eli ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Allogeneic CTL; GVH GVL; Lymphoma immunotherapy

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; EPITOPE;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC RESTRICTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC LYMPHOCYTE; FEMALE; GRAFT VERSUS HOST REACTION; LYMPHOBLAST; LYMPHOCYTE ACTIVATION; LYMPHOMA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRAFT VS HOST DISEASE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOMA; MICE; MICE, INBRED STRAINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032875048     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050563     Document Type: Article

References (64)

1. 1. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C,Collins H, Wang Y. Anderson KC, Ritz J (1998) Toxicity and efficacy of defined doses of CD4 donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation. Blood 91:3671
2. 2. Appelbaum FR (1997) Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia suppl 4:S15
3. 3. Armitage JO (1994) Bone marrow transplantation. N Engl J Med 330:827
4. 4. Barret AJ, Mavroudis D, Tisdale J, Mollderm J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnief P, Young NS, Read EJ (1998) T-cell depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21:543
5. 5. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A (1995) Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous Bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 16:283
6. 6. Bergman Y, Haimovitz J (1977) Characterization of a carcinogen-induced murine B lymphocyte cell line of C3HeB origin. Eur J Immunol 7:413
7. 7. Berke G, Rosen D, Moscovitch M (1983) T lymphocyte-mediated cytolysis. III. Delineation of mechanisms whereby mitogenic and non-mitogenic lectins mediate lymphocyte-target interaction. Immunology 49:585
8. 8. Bertz H, Burger JA, Kunzmann R, Mertelsmannn R, Finke J (1997) Adoptive immunotherapy of relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11:281
9. 9. Bonavida B, Kedar E (1974) Transplantation of allogeneic lymphoid cells specifically depleted of graft versus host reactive cells. Nature 249:658
10. 10. Bortin MM, Truitt RL, Rimm AA, Bach FH (1979) Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 281:490
11. 11. Butturini A, Gale RP (1988) T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 3:185
12. 12. Cerottini J-C, Brunner KT (1974) Cell mediated cytotoxicity,allograft rejection, and tumor immunity. Adv Immunol 18:67
13. 13. Champlin R (1991) Immunobiology of bone marrow transplantation as treatment for hematological malignancies. Transplant Proc 23:2123
14. 14. Charak BS, Agah R, Mazumder A (1992) Synergism between interleukin-2 and cyclosporine A in induction of graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 80:179
15. 15. Chen W, Reese VA, Cheever MA (1990) Adoptively transferred antigen-specific T-cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J Immunol 144:3659
16. 16. Chester SJ, Esparza AR. Albala MM (1975) Graft versus leukemia without fatal graft-versus-host disease in AKR mice. Cancer Res 35:637
17. 17. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433
18. 18. Devens B, Naor D, Kedar E (1979) Immune response to weakly immunogenic virally induced tumors. IV. Dissociated recognition of H-2 and tumor associated antigens. Transplantation 28:389
19. 19. Dunn TB, Potter M (1957) A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst 18:587
20. 20. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF(1992) Generation of leukemia reactive cytotoxic T lymphocyte clones from HLA-identical bone marrow donor of patient with leukemia. J Exp Med 176:1283
21. 21. Fidler IJ (1975) Biological behavior of malignant melanoma cells correlates to their survival in vivo.Cancer Res 35:21
22. 22. Gale RP, Champlin RE (1984) How does bone-marrow transplantation cure leukemia? Lancet 2:28
23. 23. Gately MK, Matrz E (1977) Comparative studies on the mechanism of nonspecific, ConA-dependent cytolysis and specific T-cells mediated cytolysis. J Immunol 119:1711
24. 24. Guy R, Gafanovich I, Rosenheimer N, Oron E, Yefenof E, Zilberman Y (1996) MHC-non-restricted, CD95-independent apoptosis of immature thymocytes induced by thymic epithelial cells. Cell Death Differ 3:431
25. 25. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555
26. 26. Jiang Y-Z, Kanfer EJ, Macdonald D, Cullis JO, Goldman JM, Barret AJ (1991) Graft-versus-leukemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukemia cells. Bone Marrow Transplant 8:253
27. 27. Johnson BD, Truitt RL (1992) A decrease in graft-vs-host disease without loss of graft-vs-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation 54:104
28. 28. Johnson BD, Drobyski WR, Truitt RL (1993) Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329
29. 29. Kaido T, Mauri C, Schirrmacher V, Gresser I (1994) Successful immunotherapy of the highly metastatic Esb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.Int J Cancer 15:538
30. 30. Kedar E, Weiss DW (1983) The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 38:171
31. 31. Kedar E, Rutkowski Y, Leshem B (1992) Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon α and the role of specific T cells. Cancer Immunol Immunother 35:63
32. 32. Kedar E, Gur H, Babai I, Samira S, Even-Chen S, Barenholz Y (1999) Delivery of cytokines by liposomes. IV. Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother (in press)
33. 33. Klein G, Klein E, Haughton GL (1996) Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. J Natl Cancer Inst 36:607
34. 34. Korngold R (1992) Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant 9:355
35. 35. Korngold R, Leighton C, Manser T (1994) Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58:278
36. 36. Leshem B, Brass, D. (1998) Mouse lymphoblasts lose their immunogenicity and susceptibility to specific CTL lysis during maintenance in culture. Immunology 95:409
37. 37. Leshem B, Kedar E (1990) Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization. J Exp Med 171:1057
38. 38. Leshem B, Gotsman B, Kedar E (1984) In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization. Cancer Immunol Immunother 17:117
39. 39. Leshem B, Dorfman Y, Kedar E (1993) Activation of cytotoxic lymphocytes preferentially reactive against allogeneic murine leukemias. Proceedings of EMBO workshop on cell-mediated cytotoxicity. Neve Ilan, Israel, p 58
40. 40. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206
41. 41.MacDonald HR, Cerottini J-C, Ryser JE, Maryanski JL, Taswell C, Widmer MB, Brunner KT (1980) Quantitation and cloning of cytotoxic T lymphocytes and their precursors. Immunol Rev 51:93
42. 42. Martelli MF, Aversa F (1993) Is there any future for T-cell depleted bone marrow transplantation in chronic myeloid leukaemia? Leuk Lymphoma 11 [Suppl 1]:205
43. 43. McCoy JL, Fefer A, Glynn JP (1967) Comparative studies on the induction of transplantation resistance in BALB/c and C57BL/6 mice in three murine leukemia systems. Cancer Res 27:174
44. 44. Morecki S, Yacovlev E, Diab A, Slavin S (1998) Allogeneic cell therapy for a mammary carcinoma. Cancer Res 58:3891
45. 45. Okunewick JP, Kociban DL, Machen LL, Buffo MJ (1991) The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia. Bone marrow Transplant 8:445
46. + T cells in the graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 60:35
47. 47. Parker WL, Martz E (1980) Lectin-induced nonlethal adhesion between CTL and antigenically unrecognizable tumor cells and nonspecific "triggering" of cytolysis. J Immunol 124:25
48. 48. Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA, (1985) Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 75:67
49. 49. Redd JM, Lagrade A-C, Kruse CA, Bellgrau D (1992) Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 34:349
50. 50. Reisner Y, Segall H (1995) Hematopoietic stem cell transplantation for cancer therapy. Curr Opin Immunol 7:687
51. 51. Rocha M, Umansky V, Lee KH, Hacker HJ, Benner A, Schirrmacher V (1997) Differences between graft-versus leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood 156:21
52. 52. Sebens T, Uharek L, Glass B, Muller-Ruchholtz W, Steinmann J (1995) Allogeneic mouse T cell lines distinguish three BALB/c leukemias from each other and from non-leukemia lymphocytes. Bone Marrow Transplant 16:443
53. + chronic myelogenous leukemia-specific allogeneic T lymphocytes. Cancer Res 57:15
54. 54. Slavin S. Naparstek E (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195
55. 55. Slavin S, Ackerstein A, Naparstek E, Weiss L (1990) The graft-versus-host (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 6:155
56. 56. Sosman JA, Oetell KR, Hank JA, Fisch P, Sondel PM (1989) Specific recognition of human leukemia cells by allogeneic T cell lines. Transplantation 48:486
57. 57. Steinmann J, Glass B, Herwartz C, Salomo M, Sebens T, Uharek L, Muller-Ruchholtz W (1995) In vitro generation of allogeneic rather than syngeneic cytotoxic T cells for leukemia therapy. Transplant Proc 27:637
58. 58. Sykes M, Romick ML, Sachs DH (1990) Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 87:5633
59. - and CD8-mediated graft-versus-leukemia effects. Blood 83:2560
60. 60. Sykes M, Szot GL, Nguyen PL, Pearson DA (1995) Interleukin-12 inhibits murine graft-versus-host disease. Blood 86:2429
61. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8:51
62. 62. Van Lochem E, de Gast B, Goulmy E (1991) In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181
63. 63. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemia effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529
64. 64. Yefenof E, Tchakirov R, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus-induced tumors. Cancer Immunol Immunother 8:171